search
Back to results

Preventing Isthmocele After Cesarean Section ((PICS))

Primary Purpose

Cesarean Section Complications, Uterine Scar Diverticulum, Uterine Scar From Previous Cesarean Delivery

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Non-Locking Uterine Closure
Locked Uterine Closure
Sponsored by
Mount Sinai Hospital, Canada
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cesarean Section Complications

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Women undergoing their first cesarean section

Exclusion Criteria:

  • previous uterine hysterotomy (caesarean section, myomectomy, etc.)
  • known uterine anomalies
  • active labour
  • known bleeding disorder
  • maternal connective tissue disorders

Sites / Locations

  • Mount Sinai Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Locked Uterine Closure

Non-Locking Uterine Closure

Arm Description

Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & locking technique. The second layer will be performed based on surgeon preference.

Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & non-locking technique. The second layer will be performed based on surgeon preference, but cannot be of a locking technique.

Outcomes

Primary Outcome Measures

Number of Participants Enrolled
Number of potential participants approached who actually enrolled in the trial
Number of Participants that Cross-Over
Number of participants who cross-over to the other study arm (i.e. who receive the incorrect uterine closure technique)
Number of Participants Lost to Follow Up
Number of participants enrolled in the trial who do not present for their follow up ultrasound at 6 months.

Secondary Outcome Measures

Incidence of Isthmocele
The presence of an isthmocele (minimum 2 mm x 2 mm) identified on a transvaginal ultrasound 6 months after the cesarean section
Estimated Blood Loss
Number of mL of blood lost at the time of cesarean section
Change in Hemoglobin
Change in Hgb from pre-operative measurement to Hgb measurement on post-operative day #1
Operative Time
Length of surgery (minutes)
Number of Blood Transfusions
Number of intraoperative and post-operative blood transfusions given to each participant
Additional Hemostatic Sutures
Number of additional hemostatic sutures placed in the uterus for each participant
Suture Material
Type of suture material used for hysterotomy closure
Use of Additional Oxytocin in Units
Number of units of additional oxytocin given to each participant as a uterotonic agent (beyond usual dose of intraoperative oxytocin)
Use of Ergotamine in mg
Number of mg Ergotamine used as a uterotonic agent, if required
Use of Hemabate in mg
Number of mg Ergotamine used as a uterotonic agent, if required
Use of Misoprostol in mcg
Number of mcg Misoprostol used as a uterotonic agent, if required

Full Information

First Posted
January 28, 2019
Last Updated
January 22, 2022
Sponsor
Mount Sinai Hospital, Canada
search

1. Study Identification

Unique Protocol Identification Number
NCT03826459
Brief Title
Preventing Isthmocele After Cesarean Section
Acronym
(PICS)
Official Title
The PICS Trial: A Pilot Randomized Controlled Trial of Non-Locked vs. Locked Uterine Closure at Cesarean Section for Prevention of Uterine Isthmocele Formation
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
March 5, 2019 (Actual)
Primary Completion Date
December 18, 2020 (Actual)
Study Completion Date
December 18, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mount Sinai Hospital, Canada

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Cesarean section accounts for nearly 30% of births in Canada, and is the most commonly performed surgery by Obstetrician Gynecologists. Cesarean scar isthmocele, meaning a defect in the uterine wall at the site of a previous uterine incision, is a common complication of this surgery. While most are likely asymptomatic, isthmoceles can lead to major complications in pregnancy (uterine rupture, invasive placentation, cesarean scar ectopic pregnancy) and outside of pregnancy (abnormal uterine bleeding, infertility and pain). Studies have shown that the method used to suture the uterus at the time of a cesarean section may have an impact on the incidence of post-operative isthmocele formation. Our study is a randomized control trial of the impact of locked vs unlocked uterine closure at cesarean section on the incidence of isthmocele formation. Women undergoing cesarean section will be randomized to have either a locked or unlocked uterine closure. They will then return 6 months after their surgery for a transvaginal ultrasound to evaluate the presence or absence of an isthmocele. This study is a pilot trial. The investigators hope to determine the feasibility of completing a large randomized control trial by recording: a) the number of patient who agree to participate in this study, b) the number of patients who receive the correct intervention and, c) the number of patients who return for their post operative ultrasound. The investigators also plan to assess multiple secondary outcomes. First, the goal is to determine the isthmocele incidence within the study subjects of the pilot trial in order to perform a power calculation for a subsequent larger trial in this area. Another goal is to determine if the uterine closure techniques in this study lead to differences in surgical time, blood loss or the need for intra- or post-operative blood transfusion. Last, the study will collect data on the suture material most commonly used in this study to determine if this requires standardization in the subsequent larger trial.
Detailed Description
Cesarean section accounts for nearly 30% of all deliveries in Canada, and is the most commonly performed surgery by Obstetrician Gynecologists (OBGYNs) in Canada. Therefore, it is important to understand the short and long-term complications of this procedure. Recently, emphasis has been placed on cesarean scar isthmocele as a long-term complication. An isthmocele is a defect at the cesarean section scar site with a depth of at least 1-2mm. Isthmoceles can lead to major obstetrical complications such as cesarean scar pregnancy, invasive placentation, and uterine rupture. More commonly, patients present with gynecologic symptoms: abnormal uterine bleeding, pain, and infertility. Up to 30-50% of patients with an isthmocele report symptoms when inquired. Isthmoceles have an incidence of 19-88% following cesarean section. This wide range is due to discrepancies in study technique, diagnostic criteria, and patient characteristics. While medical and surgical treatment options are available for cesarean scar isthmocele, our focus should turn to prevention at the time of cesarean section. Evidence suggests double-layer (vs. single-layer) uterine closure decreases the formation of cesarean scar isthmocele and increases residual myometrial thickness (RMT). Additionally, uterine closure with a locked suturing technique may result in greater isthmocele depth and size, and a thinner RMT at the cesarean scar site. To our knowledge however, no study has determined the impact of a locked vs. unlocked double-layer closure technique on isthmocele prevention. Locked sutures, believed to be more hemostatic, may cause tissue necrosis and impair wound healing. Interestingly, evidence does not support reductions in operative blood loss with locked closure techniques. The hypothesis is that unlocked double-layer uterine closure can reduce isthmocele formation and thus improve longterm maternal outcomes without impacting operative blood loss or other short-term surgical outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cesarean Section Complications, Uterine Scar Diverticulum, Uterine Scar From Previous Cesarean Delivery

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomized to either locked or non-locked uterine closure at the time of cesarean section.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
41 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Locked Uterine Closure
Arm Type
Active Comparator
Arm Description
Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & locking technique. The second layer will be performed based on surgeon preference.
Arm Title
Non-Locking Uterine Closure
Arm Type
Experimental
Arm Description
Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & non-locking technique. The second layer will be performed based on surgeon preference, but cannot be of a locking technique.
Intervention Type
Procedure
Intervention Name(s)
Non-Locking Uterine Closure
Intervention Description
The first layer of the two-layer uterine closure will be sutured with a running & non-locking technique. The second layer cannot be of a locking technique.
Intervention Type
Procedure
Intervention Name(s)
Locked Uterine Closure
Intervention Description
The first layer of the two-layer uterine closure will be sutured with a running & locking technique. The second layer can be locking or non-locking.
Primary Outcome Measure Information:
Title
Number of Participants Enrolled
Description
Number of potential participants approached who actually enrolled in the trial
Time Frame
6 months
Title
Number of Participants that Cross-Over
Description
Number of participants who cross-over to the other study arm (i.e. who receive the incorrect uterine closure technique)
Time Frame
6 months
Title
Number of Participants Lost to Follow Up
Description
Number of participants enrolled in the trial who do not present for their follow up ultrasound at 6 months.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Incidence of Isthmocele
Description
The presence of an isthmocele (minimum 2 mm x 2 mm) identified on a transvaginal ultrasound 6 months after the cesarean section
Time Frame
6 months
Title
Estimated Blood Loss
Description
Number of mL of blood lost at the time of cesarean section
Time Frame
Through surgery completion (estimated 1 hour)
Title
Change in Hemoglobin
Description
Change in Hgb from pre-operative measurement to Hgb measurement on post-operative day #1
Time Frame
24 hours
Title
Operative Time
Description
Length of surgery (minutes)
Time Frame
Through surgery completion (estimated 1 hour)
Title
Number of Blood Transfusions
Description
Number of intraoperative and post-operative blood transfusions given to each participant
Time Frame
Throughout hospital stay (estimated 48 hours)
Title
Additional Hemostatic Sutures
Description
Number of additional hemostatic sutures placed in the uterus for each participant
Time Frame
Start to end of surgery
Title
Suture Material
Description
Type of suture material used for hysterotomy closure
Time Frame
6 months
Title
Use of Additional Oxytocin in Units
Description
Number of units of additional oxytocin given to each participant as a uterotonic agent (beyond usual dose of intraoperative oxytocin)
Time Frame
Throughout hospital stay (estimated 48 hours)
Title
Use of Ergotamine in mg
Description
Number of mg Ergotamine used as a uterotonic agent, if required
Time Frame
Throughout hospital stay (estimated 48 hours)
Title
Use of Hemabate in mg
Description
Number of mg Ergotamine used as a uterotonic agent, if required
Time Frame
Throughout hospital stay (estimated 48 hours)
Title
Use of Misoprostol in mcg
Description
Number of mcg Misoprostol used as a uterotonic agent, if required
Time Frame
Throughout hospital stay (estimated 48 hours)

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Since this is a study done at the time of cesarean section, only females are eligible.
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women undergoing their first cesarean section Exclusion Criteria: previous uterine hysterotomy (caesarean section, myomectomy, etc.) known uterine anomalies active labour known bleeding disorder maternal connective tissue disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mara Sobel, MD
Organizational Affiliation
MOUNT SINAI HOSPITAL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G1Z5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Preventing Isthmocele After Cesarean Section

We'll reach out to this number within 24 hrs